Following neoantigen discovery and validation, mRNA construct design can be challenging. Read this case study to learn more about how to design multi-epitope mRNA constructs to optimize translation efficiency and target-specific immunogenicity while avoiding...
myNEO Therapeutics has been quite active in recent months, taking part in various conference presentations and participating in panel discussions about neoantigen discovery. Additionally, we’re pleased to announce that our CEO, Cedric, received the Medical...
Are AI-driven insights the future of precision medicine, reshaping clinical data analysis as we know it? The inherent complexity of cancer and the particular requirements for unravelling new biomarkers and predicting treatment response warrants a novel...
At myNEO Therapeutics we are devoted to finding new and better targets for immunotherapy. With our validated neoantigen discovery technology, our amazing team, and our continuous appetite for innovation, we continue this exciting path to improve cancer care for...
myNEO Therapeutics is extremely excited to announce the publication in the Cancer Cell journal, written by myNEO Therapeutics colleagues Lien, Steve, and Bruno together with key pioneers in personalized immunotherapy Patrick Ott, Sjoerd van der Burg, Kris...
myNEO Therapeutics has won Deloitte’s 2022 Most Disruptive Innovator award. This award, which is part of the Rising Star category of the Deloitte Technology Fast 50 competition, recognizes a promising company that has been active in the neoantigen discovery...
